Photosensitizer copper complex, nanoparticles / bionic nanoparticles containing the photosensitizer copper complex, and preparation method and application thereof

By developing photosensitizer copper complexes and nanoparticles that can produce reactive oxygen under laser irradiation in the treatment of oral cancer, the problem of copper ion deficiency in the tumor microenvironment is solved, and efficient induction of cancer cell death and Tumor targeting, reducing damage to normal tissue, provides a near-infrared two-zone imaging-guided treatment method.

CN118772177BActive Publication Date: 2024-11-19YANTAI UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411279875.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2024-11-19
Estimated Expiration
2044-09-12

AI Technical Summary

Technical Problem

Traditional treatments for oral cancer have trauma and significant side effects. The relative lack of copper ions in the tumor microenvironment limits its therapeutic application potential.

Method used

Develop a photosensitive agent copper complex and its nanoparticles that can produce reactive oxygen to activate copper death under laser irradiation, which has NIR-II imaging capabilities, and enhances tumor targeting and stability through bionic nanoparticles to avoid normal Tissue damage.

Benefits of technology

It has achieved efficient induction of cancer cell death under 808nm laser irradiation, with good biofusion and tumor targeting, significantly reducing the toxic effect on normal tissues, and provides a near-infrared second-zone live imaging-guided oral cancer treatment method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118772177B_ABST
    Figure CN118772177B_ABST
Patent Text Reader

Abstract

The present invention discloses a photosensitizer copper complex, nanoparticles / bionic nanoparticles containing the photosensitizer copper complex, and a preparation method and application thereof, and belongs to the field of chemical drug technology. The structural formula of the photosensitizer copper complex is shown below, the active ingredients of the nanoparticles are a copper ion carrier prodrug that can respond to active oxygen and the aforementioned photosensitizer copper complex, and the bionic nanoparticles are hybrid cell membranes that coat platelet cell membranes and tumor stem cell cell membranes on the aforementioned nanoparticles. The benefits of the present invention are that: the photosensitizer copper complex can produce active oxygen to activate copper death under the irradiation of 808nm laser and has NIR-II imaging capability, and can be used as an exogenous copper ion supply source for NIR-II imaging and anti-oral cancer treatment; the nanoparticles and bionic nanoparticles have good biocompatibility, and can avoid the photosensitizer copper complex from complexing with copper before reaching the tumor site. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a metal complex, nanoparticles containing the metal complex, a preparation method and application thereof, and in particular to a photosensitizer copper complex, nanoparticles / bionic nanoparticles containing the photosensitizer copper complex, a preparation method and application thereof, and belongs to the technical field of chemical medicines. Background Art

[0002] Oral cancer refers to malignant tumors that occur in the oral cavity, including the throat, tongue, jaw, lips, etc., and may spread to nearby lymph nodes or other parts, causing serious health problems. The most common pathological classification of oral cancer is oral squamous cell carcinoma (OSCC), which accounts for more than 90% of all oral cancers. Its traditional treatment methods include surgery, chemotherapy and radiotherapy, but they are traumatic and have significant side effects.

[0003] Copper, as an essential trace metal element in organisms, is of great significance to human health. When copper homeostasis is unbalanced, whether it is excessive or insufficient, it may seriously affect cell function and lead to a variety of diseases. 2+ It interacts with human ferredoxin 1 (FDX1) and is reduced to Cu + , leading to increased levels of reactive oxygen species (ROS) and inducing cell death. At the same time, FDX1 is a direct target of ilisimol. In 2022, the team continued to explore and discovered a unique copper-dependent cell death method that is different from apoptosis, ferroptosis, and necroptosis and named it copper death. Copper death is a new type of programmed cell death mediated by excessive intracellular copper ion levels and FDX1. This discovery also laid the research foundation for the application of copper death in the treatment of oral cancer. However, due to the relative lack of copper ions in the tumor microenvironment, the key regulatory protein FDX1 of copper death is consumed in the process of inducing copper death. These factors significantly affect the killing effect of copper death on tumor cells and limit the potential application of copper death in cancer treatment. Summary of the invention

[0004] To address the deficiencies of the prior art, the first object of the present invention is to provide a photosensitizer copper complex that can generate reactive oxygen to activate copper death under laser irradiation and has NIR-II imaging capability, and a preparation method and application thereof; the second object of the present invention is to provide a nanoparticle containing the aforementioned photosensitizer copper complex, having good biocompatibility and avoiding the aforementioned photosensitizer copper complex from complexing with copper before reaching the tumor site, and a preparation method and application thereof; the third object of the present invention is to provide a biomimetic nanoparticle containing a copper ion carrier prodrug and the aforementioned photosensitizer copper complex, which can efficiently induce copper death in cancer cells and can greatly avoid systemic toxicity to damage normal tissues, and a preparation method and application thereof.

[0005] In order to achieve the above object, the present invention adopts the following technical solution:

[0006] A photosensitizer copper complex, the structural formula of the photosensitizer copper complex is as follows:

[0007] .

[0008] The method for preparing the aforementioned photosensitizer copper complex comprises the following steps:

[0009] (1) ammonium acetate and compound 1 are dissolved in dichloromethane, and N-bromosuccinimide is added to the reaction solution in batches in an ice bath in the dark to bromine through a free radical reaction. After the reaction is completed, quenching, extraction, collecting the organic phase, drying over anhydrous Na2SO4, and concentrating under reduced pressure are sequentially performed to obtain a residue containing compound 2;

[0010] (2) placing pinacol diboron, potassium acetate and the residue obtained in step (1) in N,N-dimethylformamide, adding bistriphenylphosphine palladium dichloride under N2 atmosphere, and carrying out Suzuki coupling reaction at 85°C. After the reaction, purifying the crude product by column chromatography and drying to obtain compound 3;

[0011] (3) 4,7-dibromo-5,6-dinitrobenzo[c][1,2,5]thiadiazole, anhydrous K2CO3 and compound 3 obtained in step (2) are dissolved in a mixed solvent of toluene and water. Under the protection of N2 atmosphere, tetrakis(triphenylphosphine)palladium is added to the reaction solution. The reaction is continued under the protection of N2 atmosphere in an oil bath at 110°C for another Suzuki coupling reaction. After the reaction is completed, the crude product is purified by column chromatography and dried to obtain compound 4.

[0012] (4) NH4Cl, zinc powder and compound 4 obtained in step (3) are added to a mixed solvent of DCM and 90% methanol, and the nitro group on compound 4 is reduced by zinc powder at room temperature. After the reaction is completed, diatomaceous earth filtration is performed, the filter cake is washed with DCM, the filtrate is collected and the solvent is rotary evaporated, NH4Cl is extracted, the organic phase is collected, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a residue containing compound 5;

[0013] (5) dissolving 1,10-phenanthroline-5,6-dione and the residue obtained in step (4) in acetic acid, and refluxing in an oil bath at 120° C. to carry out a ring-closure reaction. After the reaction is completed, purifying the crude product by column chromatography, and drying to obtain compound 6;

[0014] (6) Dissolve N,N'-bis(pyridin-2-ylmethyl)prop-2-yn-1-amine and Cu(ClO4)2·6H2O in a mixed solvent of DCM and methanol, and stir at 0°C for 1 h to obtain a mixed solution. Dissolve the compound 6 obtained in step (5) in a mixed solvent of DCM and methanol and add it dropwise to the mixed solution under an ice bath. Continue to carry out metal coordination at 0°C. After the reaction is completed, centrifuge, wash the solid, and vacuum dry in sequence to obtain compound 7.

[0015] Among them, the structural formulas of compound 1, compound 2, compound 3, compound 4, compound 5 and compound 6 are shown below:

[0016] , , , , , .

[0017] The above-mentioned photosensitizer copper complex is used in the preparation of fluorescent imaging probes, or in the preparation of anti-oral cancer drugs.

[0018] A nanoparticle containing the aforementioned photosensitizer copper complex, wherein the active ingredients of the nanoparticle are a copper ion carrier prodrug capable of responding to active oxygen and the aforementioned photosensitizer copper complex, and the nanoparticle is DSPE-mPEG 2k As a scaffold, DSPE-mPEG 2k The two active ingredients are assembled together to form nanoparticles CuD@PEG, wherein the copper ion carrier prodrug capable of responding to active oxygen is DTC-BA, and its structural formula is as follows:

[0019] .

[0020] The method for preparing the aforementioned nanoparticles comprises the following steps:

[0021] (1) The aforementioned photosensitizer copper complex, copper ion carrier prodrug DTC-BA and DSPE-mPEG 2k Dissolve in chloroform to obtain a mixed solution;

[0022] (2) Under ultrasonic conditions, the mixed solution was slowly added dropwise to ultrapure water within 5 min. After the addition was completed, a micro-tip ultrasonicator was used to sonicate for another 5 min at an output power of 12 W.

[0023] (3) The organic solvent was removed by ultrafiltration using a 30 kDa MW cutoff centrifugal filter unit, and the CuD@PEG nanoparticles were obtained after drying.

[0024] The aforementioned nanoparticles CuD@PEG are used in the preparation of fluorescent imaging probes, or in the preparation of anti-oral cancer drugs.

[0025] A biomimetic nanoparticle containing the aforementioned photosensitizer copper complex, wherein the active ingredients of the biomimetic nanoparticle are a copper ion carrier prodrug capable of responding to active oxygen and the aforementioned photosensitizer copper complex, and the biomimetic nanoparticle is DSPE-mPEG 2k As a scaffold, DSPE-mPEG 2k The two active ingredients are assembled together to form nanoparticles CuD@PEG, which are then coated in a hybrid cell membrane of platelet cell membranes and tumor stem cell cell membranes to obtain biomimetic nanoparticles CuD@PM, wherein the copper ion carrier prodrug capable of responding to active oxygen is DTC-BA, and its structural formula is as follows:

[0026] .

[0027] The method for preparing the aforementioned bionic nanoparticles comprises the following steps:

[0028] (1) The aforementioned photosensitizer copper complex, copper ion carrier prodrug DTC-BA and DSPE-mPEG 2k Dissolve in chloroform to obtain a mixed solution;

[0029] (2) Under ultrasonic conditions, the mixed solution was slowly added dropwise to ultrapure water within 5 min. After the addition was completed, a micro-tip ultrasonicator was used to sonicate for another 5 min at an output power of 12 W.

[0030] (3) The organic solvent was removed by ultrafiltration using a 30 kDa MW cutoff centrifugal filter unit to obtain nanoparticles CuD@PEG;

[0031] (4) mixing the tumor stem cell membrane fragments and the platelet cell membrane fragments, and repeatedly co-extruding them through a 200 nm polycarbonate porous membrane on a membrane extruder to prepare a hybrid cell membrane;

[0032] (5) The hybrid cell membrane prepared in step (4) is mixed with the CuD@PEG nanoparticles prepared in step (3), and the mixture is repeatedly co-extruded through a 100 nm polycarbonate porous membrane on an extruder to prepare biomimetic nanoparticles CuD@PM.

[0033] The aforementioned bionic nanoparticles are used in the preparation of fluorescent imaging probes or in the preparation of anti-oral cancer drugs.

[0034] The present invention is beneficial in that:

[0035] (1) The photosensitizer copper complex (H7-Cu-BPE, compound 7) provided by the present invention can generate reactive oxygen to activate copper death under the irradiation of 808nm laser and has NIR-II imaging capability, and can be used as an exogenous copper ion supply source for NIR-II imaging and anti-oral cancer treatment;

[0036] (2) The nanoparticles CuD@PEG containing the photosensitizer copper complex (H7-Cu-BPE) provided by the present invention have good biocompatibility and can prevent H7-Cu-BPE from complexing with copper before reaching the tumor site, thereby avoiding damage to normal tissues, and can be used for near-infrared zone II in vivo imaging to guide oral cancer treatment;

[0037] (3) The present invention uses a hybrid cell membrane of platelet cell membrane and tumor stem cell cell membrane to wrap the aforementioned nanoparticle CuD@PEG to form a biomimetic nanoparticle CuD@PM. The biomimetic nanoparticle CuD@PM can not only achieve co-delivery of exogenous copper ions and copper ion carrier prodrugs, but also enhance the stability and tumor targeting of CuD@PEG in vivo, efficiently induce copper death of cancer cells, and at the same time greatly avoid systemic toxicity to normal tissue damage;

[0038] (4) Nanoparticles CuD@PEG and biomimetic nanoparticles CuD@PM can achieve good temporal and spatial resolution in biological imaging experiments. Guided by NIR-II imaging technology, they can achieve precise application of microneedles loaded with azacitidine prodrug triacetyl-azacitidine (TAc-AzaC) at the tumor site, which has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 This is the single crystal structure diagram of H7-Cu-BPE;

[0040] Figure 2 are the absorption and emission spectra of MO-H7 and H7-Cu-BPE in DMF;

[0041] Figure 3 The laser is at 808 nm (1.0 W cm -2 ) Degradation absorption spectra of DPBF by MO-H7 and H7-Cu-BPE under irradiation;

[0042] Figure 4 It is the normalized degradation graph of MO-H7 and H7-Cu-BPE to singlet oxygen indicating fluorescent probe (DPBF, 412 nm) under 808 nm laser irradiation;

[0043] Figure 5 is the transmission electron microscopy image of CuD@PM;

[0044] Figure 6 The expression results of CD61 and CD44 in platelet cell membrane, tumor stem cell cell membrane and CuD@PM detected by WB method;

[0045] Figure 7 This is the HPLC test result diagram of DTC-BA, Cu(DTC)2 and CuD@PEG before and after laser irradiation;

[0046] Figure 8 This is the calculation result of the survival rate of 4MOSC1 cells after being given different concentrations of CuD@PM;

[0047] Fig. 9 This is the NIR-II imaging result of the oral cancer C57BL / 6 mouse model after injection of CuD@PEG or CuD@PM;

[0048] Fig.10 is a graph showing the death of 4MOSC1 cells in different treatment groups;

[0049] Fig.11 is with Fig.10 Corresponding flow cytometry quantitative data analysis result diagram;

[0050] Fig.12 This is the expression result of copper death-related proteins FDX1 and DLAT in 4MOSC1 cells of different treatment groups;

[0051] Fig.13 It is the measurement result of tumor volume of 4MOSC1 tumor-bearing mice in different treatment groups;

[0052] Fig.14 CD8 in tumor tissues of 4MOSC1 tumor-bearing mice in different treatment groups + T cell number detection result diagram;

[0053] Fig.15 is with Fig.14 Corresponding flow cytometry quantitative data analysis result diagram;

[0054] Fig.16 CD80 in TDLNs of 4MOSC1 tumor-bearing mice in different treatment groups + and CD86 + Cell number detection result diagram;

[0055] Fig.17 is with Fig.16 Corresponding flow cytometry quantitative data analysis result diagram;

[0056] Fig.18 CD206 in tumors of 4MOSC1 tumor-bearing mice in different treatment groups + M2 macrophage number detection results;

[0057] Fig.19 is with Fig.18 Corresponding flow cytometry quantitative data analysis result diagram;

[0058] Fig. 20 CD25 in TDLNs of 4MOSC1 tumor-bearing mice in different treatment groups + and Foxp3 + Treg cell number detection result diagram;

[0059] Fig.21 is with Fig. 20 Corresponding flow cytometry quantitative data analysis result diagram;

[0060] Fig. 22 CD44 in TDLNs of 4MOSC1 tumor-bearing mice in different treatment groups + and CD62L + T cell number detection result diagram;

[0061] Fig.23 is with Fig. 22 Corresponding flow cytometry quantitative data analysis result diagram;

[0062] Fig.24 These are the H&E staining results of the heart, liver, spleen, lung, and kidney of 4MOSC1 tumor-bearing mice in different treatment groups. DETAILED DESCRIPTION

[0063] If no specific technology or conditions are specified in this application, they are all carried out according to the technology or conditions described in the literature published in the field, or according to the product instructions. The consumables and reagents used were purchased from the market unless otherwise specified.

[0064] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.

[0065] 1. Photosensitizer copper complex (H7-Cu-BPE) and its preparation method

[0066] The structural formula of the photosensitizer copper complex (H7-Cu-BPE) provided by the present invention is as follows:

[0067]

[0068] The synthesis route of H7-Cu-BPE provided by the present invention is as follows:

[0069] .

[0070] The synthesis method of H7-Cu-BPE provided by the present invention is as follows:

[0071] Step 1: Dissolve 6.0 g of compound 1 (4,4'-dimethoxytriphenylamine, hereinafter referred to as MO-TPA) and 151.4 mg of ammonium acetate (NH4OAc) in 100 mL of dichloromethane (DCM). Under ice bath conditions, add 3.8 g of N-bromosuccinimide (NBS) to the reaction solution in 5 batches in the dark, stir for 3 h (bromine is added through free radical reaction), and monitor the reaction progress by thin layer chromatography (TLC). After the reaction is completed, water is added to the reaction solution to quench the reaction, and the reaction is extracted three times with DCM and saturated NaCl solution. The organic phase is collected, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain 8.0 g of residue (containing compound 2, hereinafter referred to as Br-TPA). The obtained residue is not further treated and directly carried out to the next step.

[0072] Step 2: All the residues obtained in step 1 (containing Br-TPA), 6.9 g of pinacol diboron and 5.1 g of potassium acetate (KOAc) were placed in 100 mL of N, N-dimethylformamide (DMF). Under the protection of N2 atmosphere, 147.0 mg of bistriphenylphosphine palladium dichloride (Pd(PPh3)2Cl2) was added, and the mixture was heated and stirred at 85°C for 12 h (for Suzuki coupling reaction), and the reaction progress was monitored by TLC. After the reaction was completed, the crude product was purified by column chromatography, and 7.7 g of white solid was obtained after drying, with a yield of 85.3%.

[0073] After testing, the test results of the hydrogen nuclear magnetic resonance spectrum, carbon nuclear magnetic resonance spectrum and mass spectrum of the white solid are as follows:

[0074] 1 H NMR (600MHz, CDCl3) δ7.60 (d, J=8.0Hz, 2H), 7.07 (d, J=8.8Hz, 4H), 6.87 (d, J=8.1Hz, 2H), 6.83 (d, J=8.4Hz, 4H), 3.80 (s, 6H), 1.32 (s, 12H).

[0075] 13 C NMR (151MHz, CDCl3) δ156.3, 151.5, 140.5, 135.9, 127.3, 118.8, 114.8, 83.5, 55.6, 25.0, 1.2.

[0076] HR-MS (ESI): m / z [M+H] + C 27 H 30 The calculated value of the molecular weight of BNO4 is 432.23, and the theoretical value is 431.23.

[0077] Based on the detection results of the above-mentioned hydrogen nuclear magnetic resonance spectrum, carbon nuclear magnetic resonance spectrum and mass spectrum, it can be determined that the white solid is compound 3 (hereinafter referred to as MO-BZ).

[0078] Step 3: 1.6 g of MO-BZ obtained in step 2, 634.0 mg of 4,7-dibromo-5,6-dinitrobenzo[c][1,2,5]thiadiazole and 684.6 mg of anhydrous K2CO3 were dissolved in 25 mL of a mixed solvent of toluene and water (the volume ratio of toluene to water was 4:1). Under the protection of N2 atmosphere, 190.7 mg of tetrakis(triphenylphosphine)palladium (Pd(PPh3)4) was added to the reaction solution. Stirring was continued in an oil bath at 110°C for 48 h under the protection of N2 atmosphere (another Suzuki coupling reaction was performed), and the reaction progress was monitored by TLC. After the reaction was completed, the crude product was purified by column chromatography, and 300 mg of a purple solid was obtained after drying, with a yield of 21.8%.

[0079] After testing, the results of hydrogen nuclear magnetic resonance spectrum, carbon nuclear magnetic resonance spectrum and mass spectrum of the purple solid are as follows:

[0080] 1 H NMR (600MHz, CDCl3) δ7.36 (d, J=8.8Hz, 4H), 7.19-7.15 (m, 8H), 6.95 (d, J=8.8Hz, 4H), 6.91-6.87 (m, 8H), 3.81 (s, 12H).

[0081] 13 C NMR (151MHz, CDCl3) δ157.0, 153.4, 150.7, 142.3, 139.6, 130.3, 128.0, 127.9, 120.6, 117.9, 115.1, 55.6.

[0082] HR-MS (ESI): m / z [M+H] + C 46 H 36 The calculated value of the molecular weight of SN6O8 is 833.24, and the theoretical value is 832.23.

[0083] Based on the detection results of the above-mentioned nuclear magnetic resonance hydrogen spectrum, nuclear magnetic resonance carbon spectrum and mass spectrum, it can be determined that the purple solid is compound 4 (hereinafter referred to as MO-TMT).

[0084] Step 4: Add 85.8 mg of MO-TMT obtained in step 3, 198.4 mg of NH4Cl and 808.3 mg of zinc powder to 10 mL of DCM and 95% methanol mixed solvent (the volume ratio of DCM and 95% methanol is 1:1). Stir the reaction at room temperature for 3 h (zinc powder reduces the nitro group on MO-TMT), and monitor the reaction progress by TLC. After the reaction is completed, the zinc powder is first filtered out with diatomaceous earth, and then the filter cake is washed with DCM. The filtrate is collected and the solvent is rotary evaporated. Then, NH4Cl is extracted from the residue after rotary evaporation with DCM and water. The organic phase is collected, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a yellow residue (containing compound 5, hereinafter referred to as MO-TNT). The obtained yellow residue is not further treated and directly proceeds to the next step.

[0085] Step 5: All the yellow residues obtained in step 4 (containing MO-TNT) and 26.0 mg of 1,10-phenanthroline-5,6-dione were dissolved in 5 mL of acetic acid, refluxed in an oil bath at 120°C for 4 h (ring closure reaction occurred), and the reaction progress was monitored by TLC. After the reaction was completed, the crude product was purified by column chromatography, and 32.7 mg of green solid was obtained after drying, with a yield of 32.9%.

[0086] After testing, the test results of the hydrogen nuclear magnetic resonance spectrum, carbon nuclear magnetic resonance spectrum and mass spectrum of the green solid are as follows:

[0087] 1 H NMR (400MHz, CDCl3) δ9.50 (dd, J=8.2, 1.6Hz, 2H), 9.23-9.17 (m, 2H), 8.09 (dd, J=8.1, 4.9Hz, 2 H), 8.00-7.94 (m, 4H), 7.33-7.27 (m, 8H), 7.24-7.17 (m, 4H), 6.97-6.91 (m, 8H), 3.85 (s, 12H).

[0088] 13 C NMR (151MHz, CDCl3) δ156.5, 153.1, 152.9, 149.2, 141.8, 140.6, 137.3, 13 4.5, 134.2, 129.9, 129.0, 128.0, 127.6, 126.6, 124.6, 118.4, 115.0, 55.7.

[0089] HR-MS (ESI): m / z [M+H] + C 58 H 42 The calculated value of the molecular weight of SN8O4 is 947.31, and the theoretical value is 947.30.

[0090] Based on the detection results of the above-mentioned hydrogen nuclear magnetic resonance spectrum, carbon nuclear magnetic resonance spectrum and mass spectrum, it can be determined that the green solid is compound 6 (hereinafter referred to as MO-H7).

[0091] Step 6: Dissolve 2.5 mg of N, N'-bis(pyridin-2-ylmethyl)prop-2-yn-1-amine and 3.9 mg of Cu(ClO4)2·6H2O in 1 mL of a mixed solvent of DCM and methanol (the volume ratio of DCM and methanol is 1:1), and stir at 0°C for 1 h to obtain a mixed solution. Then, dissolve 10.0 mg of MO-H7 obtained in step 5 in 1 mL of a mixed solvent of DCM and methanol (the volume ratio of DCM and methanol is 1:1), and add dropwise to the mixed solution under an ice bath. Continue stirring at 0°C for 4 h (for metal coordination), and a yellow-green precipitate is clearly visible. After the reaction is completed, centrifuge and remove the supernatant. Wash the solid with a mixed solvent of DCM and methanol (the volume ratio of DCM and methanol is 1:1) until the supernatant is colorless. Pour off the supernatant, and vacuum dry the remaining solid to obtain a yellow-green solid.

[0092] The single crystal structure of the yellow-green solid is as follows Figure 1 The detailed data of the single crystal structure are shown in Table 1.

[0093] Table 1 Crystal data and structure refinement of H7-Cu-BPE

[0094]

[0095]

[0096] The above crystal structure detection results can determine that the yellow-green solid is compound 7 (hereinafter referred to as H7-Cu-BPE), which is a copper complex of compound 6.

[0097] The absorption and emission spectra of MO-H7 and H7-Cu-BPE in DMF are shown in Figure 2 .Depend on Figure 2 It can be seen that the maximum absorption peak of H7-Cu-BPE is at 756nm, and the maximum emission peak is at 1135nm, which show a certain degree of red shift compared to the maximum absorption of 736nm and the maximum emission of 1021nm of MO-H7. This provides a spectroscopic theoretical basis for H7-Cu-BPE in near-infrared second zone imaging-guided tumor therapy.

[0098] The reactive oxygen species (ROS) generation levels of the two molecules (MO-H7 and H7-Cu-BPE) before and after copper complexation were compared. Using 1,3-diphenylisobenzofuran (DPBF) as an indicator, the ROS generation capacity of MO-H7 and H7-Cu-BPE in the DMF / H2O system was detected. Specifically: MO-H7, H7-Cu-BPE and DPBF were prepared into 2mM mother solutions with DMF and placed in EP tubes (DPBF was kept away from light). 5 μL of MO-H7 or H7-Cu-BPE stock solution was placed in a UV transparent quartz 96-well ELISA plate, and then 10 μL of DPBF stock solution was added, followed by 65 μL of DMF and 120 μL of H2O to prepare a test solution with a total volume of 200 μL and a water content of 60% (the final concentrations of MO-H7 and H7-Cu-BPE were both 50 μM, and the final concentration of DPBF was 100 μM). Finally, the samples were illuminated with an 808 nm laser (1.0 W cm -2 ) Irradiate the test solution for 30 seconds each, measure the UV-visible absorption spectrum of the solution in the range of 300-900 nm with an enzyme marker, and observe the change in absorbance of the solution at 412 nm. The total irradiation time is 300 seconds.

[0099] At 808 nm laser (1.0 W cm -2 ) irradiation, the degradation absorption spectra of DPBF by MO-H7 and H7-Cu-BPE are shown in Figure 3 .Depend on Figure 3 It can be seen that under the same illumination time, H7-Cu-BPE has a stronger ability to degrade DPBF, that is, H7-Cu-BPE has a stronger ability to produce ROS.

[0100] At 808 nm laser (1.0 W cm -2 ) irradiation, the normalized degradation diagram of MO-H7 and H7-Cu-BPE to DPBF is shown in Figure 4 .Depend on Figure 4 It can be seen that k MO-H7 =-0.0008391, k H7-Cu-BPE =-0.002961.

[0101] The calculation formulas for the ROS generation efficiency of MO-H7 and H7-Cu-BPE are as follows:

[0102]

[0103] Among them, Φ MO-H7 , Φ H7-Cu-BPE and Φ ICG are the ROS generation efficiencies of MO-H7, H7-Cu-BPE and indocyanine green, k MO-H7 , k H7-Cu-BPE and kICG MO-H7, H7-Cu-BPE and indocyanine green were respectively exposed to 808 nm laser (1.0 W·cm -2 ) is the slope of the normalized degradation graph of DPBF under irradiation, F MO-H7 、F H7-Cu-BPE and F ICG The absorption correction factors of MO-H7, H7-Cu-BPE and indocyanine green, F=1-10 OD808nm , O.D. 808nm is the absorbance value of the sample measured at 808 nm. Taking 30 s of illumination as an example, the absorbance values ​​of MO-H7 and H7-Cu-BPE measured at 808 nm are 0.238828 and 0.132852, respectively. Correspondingly, the absorption correction factors of MO-H7 and H7-Cu-BPE are -0.7331 and -0.3579, respectively.

[0104] According to the calculation formula of the ROS generation efficiency of MO-H7 and H7-Cu-BPE, the relative ROS generation efficiency of H7-Cu-BPE relative to MO-H7 can be derived, that is:

[0105]

[0106] After calculation, the relative ROS generation efficiency of H7-Cu-BPE relative to MO-H7 is 7.228, that is, the ROS generation efficiency of H7-Cu-BPE is 7.228 times that of MO-H7. It can be seen that H7-Cu-BPE has stronger photodynamic performance.

[0107] 2. Nanoparticles containing photosensitizer copper complex (CuD@PEG) and preparation method thereof

[0108] The nanoparticles provided by the present invention have two active ingredients, namely: a copper ion carrier prodrug that can respond to active oxygen and the aforementioned photosensitizer copper complex (H7-Cu-BPE). Among them, the copper ion carrier prodrug that can respond to active oxygen is DTC-BA, and its structural formula is as follows:

[0109] .

[0110] 1. Synthesis of copper ion carrier prodrug DTC-BA

[0111] The synthetic route of DTC-BA is as follows:

[0112]

[0113] The synthesis method of DTC-BA is as follows:

[0114] 1.7 g of sodium diethyldithiocarbamate and 214.0 mg of 4-(bromomethyl)phenylboronic acid (BBr-BA) were added to 15 mL of a mixed solvent of acetonitrile and ethanol (the volume ratio of acetonitrile to ethanol was 2:1). The mixture was ultrasonically treated for 15 min and then stirred at room temperature overnight until the reaction solution became transparent. The solvent was then removed by rotary evaporation, and 50 mL of ethyl acetate was added to dissolve the residue and extracted three times with water. The organic phase was collected and dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure. A white solid was obtained after drying.

[0115] After testing, the test results of the hydrogen nuclear magnetic resonance spectrum, carbon nuclear magnetic resonance spectrum and mass spectrum of the white solid are as follows:

[0116] 1 H NMR (600MHz, CDCl3) δ8.15 (d, J =7.5Hz, 2H), 7.52(d, J =7.6Hz, 2H), 4.63 (s, 2H), 4.06 (q, J =7.1Hz, 2H), 3.75(q, J =7.2Hz, 2H), 1.30(td, J =7.1, 2.7 Hz, 6H);

[0117] 13 C NMR (151 MHz, chloroform-d) δ 194.8, 141.0, 135.7, 128.9, 49.5, 46.7, 42.0, 11.5;

[0118] LC-MS: m / z [M+H] + C 12 H 18 The theoretical value of the molecular weight of BNO2S2 is 283.09, and the calculated value is 284.20.

[0119] The structural formula of the white solid can be determined from the detection results of the above hydrogen nuclear magnetic resonance spectrum, carbon nuclear magnetic resonance spectrum and mass spectrum:

[0120] .

[0121] 2. Assemble H7-Cu-BPE and DTC-BA into nanoparticles

[0122] 3 mg H7-Cu-BPE, 2 mg DTC-BA and 24 mg methoxy-polyethylene glycol-phospholipid (DSPE-mPEG 2k, scaffold) was dissolved in 1 mL of chloroform (CHCl3) to obtain a mixed solution. Under ultrasonic conditions, the mixed solution was slowly added to 40 mL of ultrapure water within 5 minutes. After the addition was completed, a micro-tip ultrasonicator was used to ultrasonicate for another 5 minutes at an output power of 12 W. Then, the organic solvent was removed by ultrafiltration at 4000 rpm using a 30 kDa MW cutoff centrifugal filter unit to obtain nanoparticles containing H7-Cu-BPE, which were recorded as CuD@PEG.

[0123] After testing, the average hydrodynamic particle size of CuD@PEG was about 70.45nm.

[0124] 3. Biomimetic nanoparticles containing photosensitizer copper complex (CuD@PM) and preparation method thereof

[0125] 1. Obtaining tumor stem cell membrane fragments

[0126] Stem cells were obtained from cultured tumor spheres and suspended in a hypotonic lysis buffer, and then the stem cells were broken with a homogenizer to obtain a stem cell solution. The stem cell solution was then treated with deoxyribonuclease A (DNase A) and ribonuclease I (RNaseI) successively, and then centrifuged at 3200g for 5 minutes, the supernatant was collected, and then centrifuged at 20000g for 30 minutes, the supernatant was collected, and the precipitate was collected by centrifugation at 80000g for 1.5 hours, and then the precipitate was washed three times with PBS containing protease inhibitors, and then ultrasonically broken for 5 minutes to obtain tumor stem cell cell membrane fragments.

[0127] 2. Obtaining platelet cell membrane fragments

[0128] Mouse whole blood was centrifuged at 100 g for 20 min, the supernatant was collected, and then centrifuged at 800 g for 20 min to collect the precipitate (platelets), which was washed three times with PBS and then frozen at -80 °C, subsequently thawed at 25 °C, and then centrifuged at 4000 g for 3 min to obtain platelet cell membrane fragments.

[0129] 3. Obtaining hybrid cell membrane

[0130] The tumor stem cell membrane fragments and platelet cell membrane fragments obtained above were mixed at a mass ratio of 1:1, and then repeatedly co-extruded on a membrane extruder through a 200 nm polycarbonate porous membrane to prepare a hybrid cell membrane.

[0131] 4. Preparation of biomimetic nanoparticles

[0132] The hybrid cell membrane prepared above was mixed with the CuD@PEG prepared above at a mass ratio of 2:1, and then repeatedly co-extruded through a 100 nm polycarbonate porous membrane on a film extruder to prepare bionic nanoparticles containing H7-Cu-BPE, which were recorded as CuD@PM.

[0133] Transmission electron microscope image of CuD@PM is shown in Figure 5 .Depend on Figure 5 It can be seen that the average hydrodynamic particle size of CuD@PM is about 97.14nm.

[0134] 5. Characterize membrane proteins

[0135] The membrane proteins of platelet cell membrane, tumor stem cell cell membrane and CuD@PM were characterized by protein immunoblotting (WB method).

[0136] Membrane protein characterization results are shown in Figure 6 .Depend on Figure 6 It can be seen that the platelet cell membrane only expresses CD61, and the tumor stem cell cell membrane only expresses CD44. CD61 and CD44 are markers of the platelet cell membrane and the tumor stem cell cell membrane, respectively; CuD@PM simultaneously expresses the tumor stem cell cell membrane marker CD44 and the platelet cell membrane marker CD61, which indicates that the hybrid membrane is successfully coated on CuD@PEG.

[0137] 4. Verify whether CuD@PEG can achieve light-controlled site-specific activation to induce copper death

[0138] First, the standard substances DTC-BA and Cu(DTC)2 were detected by HPLC.

[0139] Then, the CuD@PEG prepared above was detected by HPLC.

[0140] Then, 808 nm and 1.5 W cm -2 The CuD@PEG mother solution was irradiated with laser for 1 h and then subjected to HPLC detection again.

[0141] The HPLC test results of standard DTC-BA and Cu(DTC)2 as well as CuD@PEG before and after laser irradiation are shown in Figure 7 .Depend on Figure 7It can be seen that after 1 hour of light exposure, the DTC-BA peak with a retention time of about 10 minutes disappeared, while the Cu(DTC)2 peak with a retention time of about 6 minutes appeared. This shows that the DTC-BA in CuD@PEG was cleaved in response to ROS, releasing DTC, and the free DTC competed for complexing copper ions to generate Cu(DTC)2. In other words, CuD@PEG can trigger the release of DTC in response to ROS through light control, and DTC competes for complexing copper ions, thereby achieving light-controlled site-specific activation to induce copper death.

[0142] 5. Detection of cytotoxicity of CuD@PM

[0143] The cytotoxicity was determined using the CCK-8 kit (Cell Counting Kit-8). 5 × 10 3 The mouse oral squamous cell carcinoma cell line 4MOSC1 cells were inoculated on a transparent 96-well plate at a cell density of 100 μg / cm2 and cultured overnight. The wells where the cells were plated were surrounded with PBS to prevent the culture medium from drying out and affecting cell growth. After the cells reached a density of 70-80%, the original culture medium was replaced with fresh culture medium containing different concentrations (0 μM, 0.1 μM, 0.3 μM, 0.5 μM, 1.0 μM) of CuD@PM. Three replicate wells were set for each concentration, with 100 μL per well. The laser irradiation group was given 808 nm laser (1.0 W·cm -2 The cells were irradiated for 3 minutes (10 min, 3 min) and the non-irradiated group was not irradiated. The cells were then incubated in the dark for 24 hours, and then 100 μL of culture medium containing 10% CCK-8 reagent was added to each well, followed by another 2.5 hours of incubation in the dark. After the incubation, the absorbance value (OD) of each well was measured at a wavelength of 450 nm using an ELISA reader. 450 ). The cell survival rate was calculated based on the measured absorbance value, and the calculation formula is as follows:

[0144] Survival rate (%) = (OD 450-样品 -OD 450-空白 ) / (OD 450-对照 -OD 450-空白 )×100%.

[0145] The survival rate calculation results of 4MOSC1 cells after administration of different concentrations of CuD@PM are shown in Figure 8 .Depend on Figure 8 It can be seen that after incubating 4MOSC1 cells with different concentrations of CuD@PM for 24 hours, the survival rate of tumor cells in the laser-irradiated group was significantly lower than that in the non-laser-irradiated group, and the half-lethal rate was below 1.0 μM when the concentration of CuD@PM was 1.0 μM. This shows that CuD@PM has good anti-tumor activity after light activation.

[0146] VI. Verification of the fluorescence imaging ability and tumor targeting enrichment ability of CuD@PEG and CuD@PM

[0147] CuD@PEG and CuD@PM (200 μL, 1 mg / kg Cu, 15 mg / kg DTC) were injected into the oral cancer C57BL / 6 mouse model (n=3) via the tail vein. The mouse model was then anesthetized with sodium pentobarbital solution (50 mg / kg) and placed in a supine position under the laser of a small animal imager at 808 nm (90 mW·cm -2 ) laser irradiation, using a long-pass 1000nm filter, all mouse models (in vivo) were imaged in the near-infrared II region (NIR-II) with the same exposure time and the same platform height at predetermined time points (30min, 5h, 10h, 24h, 32h, 56h).

[0148] The NIR-II imaging results of the oral cancer C57BL / 6 mouse model after injection of CuD@PEG or CuD@PM are shown in Fig. 9 .Depend on Fig. 9 It can be seen that 30 minutes after the injection of CuD@PEG or CuD@PM, CuD@PEG and CuD@PM can be clearly seen to be enriched in the sublingual tumor of mice. As time goes by, CuD@PEG and CuD@PM accumulate in the tumor site, and the NIR-II signal of the sublingual tumor site gradually increases and reaches the maximum value at 24 hours. It can be seen that both CuD@PEG and CuD@PM have good fluorescence imaging capabilities and targeted tumor enrichment capabilities.

[0149] VII. Apoptosis detection of CuD@PM combined with azacitidine (5-AzaC) induced copper death

[0150] The cultured mouse oral squamous cell carcinoma cell line 4MOSC1 cells were divided into seven groups and then treated differently, including:

[0151] Laser irradiation group: 5-AzaC and CuD@PM were not added to the culture medium, and 808 nm laser (1.0 W cm -2 , 3min) irradiation;

[0152] 5-AzaC group: the original culture medium was replaced with fresh culture medium containing 5.0 μM 5-AzaC, and no laser irradiation was performed;

[0153] CuD@PM group: the original culture medium was replaced with fresh culture medium containing 1.0 μM CuD@PM, and no laser irradiation was performed;

[0154] 5-AzaC+CuD@PM group: the original culture medium was replaced with fresh culture medium containing 1.0 μM CuD@PM and 5.0 μM 5-AzaC, and no laser irradiation was performed;

[0155] Laser irradiation + 5-AzaC group: The original culture medium was replaced with fresh culture medium containing 5.0 μM 5-AzaC, and 808 nm laser (1.0 W cm -2 , 3min) irradiation;

[0156] Laser irradiation + CuD@PM group: The original culture medium was replaced with fresh culture medium containing 1.0 μM CuD@PM, and 808 nm laser (1.0 W·cm -2 , 3min) irradiation;

[0157] Laser irradiation + 5-AzaC + CuD@PM group: The original culture medium was replaced with fresh culture medium containing 1.0 μM CuD@PM and 5.0 μM 5-AzaC, and 808 nm laser (1.0 W·cm -2 , 3min) irradiation.

[0158] After treatment, the 4MOSC1 cells in each treatment group were collected, centrifuged and the supernatant was discarded, and the cells were gently resuspended with 500 μL PBS buffer. The annexin V-FITC / PI apoptosis detection kit (purchased from Chamot Biotechnologies) was used according to the instructions. The 4MOSC1 cells in each treatment group were then analyzed using a Beckman CytoFLEX flow cytometer, and the event count for each sample was 10,000 (to ensure statistical relevance).

[0159] The death of 4MOSC1 cells in each treatment group is shown in Fig.10 ,and Fig.10 The corresponding flow cytometry data analysis results are shown in Fig.11 .Depend on Fig.10 and Fig.11 It can be seen that the laser irradiation + 5-AzaC + CuD@PM group significantly increased the number of PI-positive cells. This shows that CuD@PM combined with azacitidine has a stronger ability to kill tumor cells under 808nm laser irradiation.

[0160] 8. Detection of the expression of proteins related to copper death induced by CuD@PM combined with 5-AzaC

[0161] The cultured mouse oral squamous cell carcinoma cell line 4MOSC1 cells were divided into two groups and then treated differently:

[0162] Laser irradiation group: 5-AzaC and CuD@PM were not added to the culture medium, and 808 nm laser (1.0 W cm -2 , 3min) irradiation;

[0163] Laser irradiation + 5-AzaC + CuD@PM group: The original culture medium was replaced with fresh culture medium containing 1.0 μM CuD@PM and 5 μM 5-AzaC, and 808 nm laser (1.0 W cm -2 , 3min) irradiation.

[0164] After treatment, 4MOSC1 cells from each treatment group were collected and analyzed for copper death-related proteins DLAT and FDX1 by WB.

[0165] The expression of copper death-related proteins DLAT and FDX1 in 4MOSC1 cells of each treatment group is shown in Fig.12 .Depend on Fig.12 It can be seen that the amount of FDX1 in the laser irradiation + 5-AzaC + CuD@PM group decreased (indicating that copper death occurred and consumed FDX1). At the same time, 180kDa acylated DLAT protein oligomers appeared (the molecular weight of DLAT before aggregation was 70kDa, proving the occurrence of copper death).

[0166] IX. Study on the anti-tumor therapeutic effect of CuD@PM combined with 5-AzaC inducing copper death in vivo

[0167] Equal amounts of 4MOSC1 cells were inoculated sublingually in C57BL / 6 mice. Seven days later, these 4MOSC1 tumor-bearing mice were randomly divided into seven groups (5 mice in each group) and then given different treatments:

[0168] Laser irradiation group: 808 nm laser (1.0 W cm -2 , 3min) irradiation;

[0169] TAc-AzaC group: TAc-AzaC (1 mg / kg) was administered by microneedle at the tumor site without laser irradiation;

[0170] CuD@PM group: CuD@PM (200 μL, 1 mg / kg Cu, 15 mg / kg DTC) was injected into the tail vein without laser irradiation;

[0171] TAc-AzaC+CuD@PM group: CuD@PM (200 μL, 1 mg / kg Cu, 15 mg / kg DTC) was injected into the tail vein, and 30 min later, microneedle administration (1 mg / kg) containing TAc-AzaC was guided by imaging, without laser irradiation;

[0172] Laser irradiation + TAc-AzaC group: TAc-AzaC (1 mg / kg) was administered by microneedle at the tumor site, and 808 nm laser (1.0 W·cm -2 , 3min) irradiation;

[0173] Laser irradiation + CuD@PM group: CuD@PM (200 μL, 1 mg / kg Cu, 15 mg / kg DTC) was injected into the tail vein, and 808 nm laser (1.0 W·cm -2 , 3min) irradiation;

[0174] Laser irradiation + TAc-AzaC + CuD@PM group: CuD@PM (200 μL, 1 mg / kg Cu, 15 mg / kg DTC) was injected into the tail vein. After 30 minutes, microneedle administration of TAc-AzaC (1 mg / kg) was guided by imaging. After 24 hours, 808 nm laser (1.0 W·cm -2 , 3min) irradiation.

[0175] During the experiment, starting from the 5th day after the 4MOSC1 tumor-bearing mice were inoculated with 4MOSC1 cells, the tumor volume was recorded every other day. On the 16th day of inoculation (i.e., 8 days after treatment), the 4MOSC1 tumor-bearing mice in each treatment group were killed by cervical dislocation.

[0176] The tumor volume measurements of 4MOSC1 tumor-bearing mice in each treatment group are shown in Fig.13 .Depend on Fig.13 It can be seen that the laser irradiation + CuD@PM group can significantly inhibit tumor growth compared with the laser irradiation group. Compared with other treatments, the combined treatment of laser irradiation + TAc-AzaC + CuD@PM showed better anti-tumor efficacy. This shows that the strategy of upregulating the key protein of copper death by azacitidine and then delivering copper ions to tumors through CuD@PM to enhance the sensitivity of tumor cells to copper-induced cell death has excellent anti-tumor effects.

[0177] 10. Detection of immune activation level of CuD@PM combined with 5-AzaC-induced copper death

[0178] The 4MOSC1 tumor-bearing mice in each treatment group that were sacrificed by cervical dislocation were dissected to obtain tumors and tumor-draining lymph nodes (TDLNs), and single-cell suspensions were prepared for immuno-flow cytometry validation. The gating scheme was as follows:

[0179] In tumors: CD45 + CD3 + CD8 + T cells, CD45 + CD11b+ F4 / 80 + CD206 + M2 macrophages and CD45 + CD3 + CD4 + CD25 + Foxp3 + Treg cells;

[0180] TDLNs: CD45 + CD11c + CD80 + CD86 + Dendritic cells and CD45 + CD3 + CD8 + CD44 + CD62L + Effector memory T cells.

[0181] The results showed that the number of CD8 + The number of T cells is shown in Fig.14 ,and Fig.14 The corresponding flow cytometry data analysis results are shown in Fig.15 ; CD80 in TDLNs of MOSC1 tumor-bearing mice in each treatment group + and CD86 + The number of cells is shown in Fig.16 ,and Fig.16 The corresponding flow cytometry data analysis results are shown in Fig.17 .Depend on Fig.14 and Fig.15 It can be seen that compared with the other treatment groups, the CD8 + The number of T cells increased significantly. Fig.16 and Fig.17 It can be seen that compared with the other treatment groups, the CD80 + and CD86 + The number of double-positive dendritic cells increased significantly, suggesting that the combined treatment enhanced the anti-tumor immune response by promoting the infiltration and activation of cytotoxic T cells, which play a key role in killing cancer cells.

[0182] CD206 in tumors of 4MOSC1 tumor-bearing mice in each treatment group + The number of M2 macrophages is shown in Fig.18 ,and Fig.18The corresponding flow cytometry data analysis results are shown in Fig.19 ; CD25 in TDLNs of 4MOSC1 tumor-bearing mice in each treatment group + and Foxp3 + The number of Treg cells is shown in Fig. 20 ,and Fig. 20 The corresponding flow cytometry data analysis results are shown in Fig.21 .Depend on Fig.18 , Fig.19 , Fig. 20 and Fig.21 It can be seen that the F4 / 80 in the tumors treated with laser irradiation + TAc-AzaC + CuD@PM group + CD206 + Double positive M2 macrophages and CD25 + Foxp3 + The number of double-positive Treg cells was significantly reduced compared with other groups, which indicates that this treatment strategy changes the tumor immune microenvironment and activates the immune killing effect on tumor cells.

[0183] CD44 in TDLNs of 4MOSC1 tumor-bearing mice in each treatment group + and CD62L + The number of T cells is shown in Fig. 22 ,and Fig. 22 The corresponding flow cytometry data analysis results are shown in Fig.23 .Depend on Fig. 22 and Fig.23 It can be seen that compared with the other treatment groups, the CD44 + and CD62 + The increase in the number of double-positive effector memory T cells can enhance rapid and specific secondary immune responses.

[0184] Through the above analysis of the number of immune cells in tumors and TDLNs, it can be seen that CuD@PM and the combined administration of azacitidine significantly activated the immune microenvironment of the tumor, increasing the immune synergy for tumor treatment.

[0185] XI. Pathological safety examination of CuD@PM combined with 5-AzaC to induce copper death

[0186] The 4MOSC1 tumor-bearing mice in each treatment group, which were sacrificed by cervical dislocation, were dissected to obtain the heart, liver, spleen, lung, and kidney, and these organs were subjected to histopathological examination by hematoxylin-eosin (H&E) staining.

[0187] The results of H&E staining of the heart, liver, spleen, lung, and kidney of 4MOSC1 tumor-bearing mice in each treatment group are shown in Fig.24 .Depend on Fig.24 It can be seen that there were no significant abnormalities in the cell morphology of the main organs of 4MOSC1 tumor-bearing mice in each treatment group. In summary, the combined treatment of laser irradiation + TAc-AzaC + CuD@PM did not cause any significant histological damage, and this treatment strategy is safe.

[0188] It should be noted that the above embodiments are merely examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is impossible to list all the embodiments here. Any obvious changes or modifications derived from the technical solution of the present invention are still within the scope of protection of the present invention.

Claims

1. A photosensitizer copper complex, characterized in that The structural formula of the photosensitizer copper complex is as follows: 。 2. The method for preparing the photosensitizer copper complex according to claim 1, characterized in that: The following steps are involved: (1) ammonium acetate and compound 1 are dissolved in dichloromethane, and N-bromosuccinimide is added to the reaction solution in batches in an ice bath in the dark to bromine through a free radical reaction. After the reaction is completed, quenching, extraction, collecting the organic phase, drying over anhydrous Na2SO4, and concentrating under reduced pressure are sequentially performed to obtain a residue containing compound 2; (2) placing pinacol diboron, potassium acetate and the residue obtained in step (1) in N,N-dimethylformamide, adding bistriphenylphosphine palladium dichloride under N2 atmosphere, and carrying out Suzuki coupling reaction at 85°C. After the reaction, purifying the crude product by column chromatography and drying to obtain compound 3; (3) 4,7-dibromo-5,6-dinitrobenzo[c][1,2,5]thiadiazole, anhydrous K2CO3 and compound 3 obtained in step (2) are dissolved in a mixed solvent of toluene and water. Under the protection of N2 atmosphere, tetrakis(triphenylphosphine)palladium is added to the reaction solution. The reaction is continued under the protection of N2 atmosphere in an oil bath at 110°C for another Suzuki coupling reaction. After the reaction is completed, the crude product is purified by column chromatography and dried to obtain compound 4. (4) NH4Cl, zinc powder and compound 4 obtained in step (3) are added to a mixed solvent of DCM and 90% methanol, and the nitro group on compound 4 is reduced by zinc powder at room temperature. After the reaction is completed, diatomaceous earth filtration is performed, the filter cake is washed with DCM, the filtrate is collected and the solvent is rotary evaporated, NH4Cl is extracted, the organic phase is collected, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a residue containing compound 5; (5) dissolving 1,10-phenanthroline-5,6-dione and the residue obtained in step (4) in acetic acid, and refluxing in an oil bath at 120° C. to carry out a ring-closure reaction. After the reaction is completed, purifying the crude product by column chromatography, and drying to obtain compound 6; (6) Dissolve N,N'-bis(pyridin-2-ylmethyl)prop-2-yn-1-amine and Cu(ClO4)2·6H2O in a mixed solvent of DCM and methanol, and stir at 0°C for 1 h to obtain a mixed solution. Dissolve the compound 6 obtained in step (5) in a mixed solvent of DCM and methanol and add the mixture dropwise to the mixed solution under an ice bath. Continue to carry out metal coordination at 0°C. After the reaction is completed, centrifuge, wash the solid, and vacuum dry in sequence to obtain a photosensitizer copper complex. Among them, the structural formulas of compound 1, compound 2, compound 3, compound 4, compound 5 and compound 6 are shown below: 、 、 、 、 、 。 3. Use of the photosensitizer copper complex according to claim 1 in the preparation of a fluorescent imaging probe, or in the preparation of an anti-oral cancer drug.

4. A nanoparticle containing the photosensitizer copper complex according to claim 1, characterized in that: The active ingredients of the nanoparticles are a copper ion carrier prodrug that can respond to active oxygen and the photosensitizer copper complex of claim 1. The nanoparticles are DSPE-mPEG 2k As a scaffold, DSPE-mPEG 2k The two active ingredients are assembled together to form nanoparticles CuD@PEG, wherein the copper ion carrier prodrug capable of responding to active oxygen is DTC-BA, and its structural formula is as follows: 。 5. The method for preparing nanoparticles according to claim 4, characterized in that: The following steps are involved: (1) The photosensitizer copper complex, copper ion carrier prodrug DTC-BA and DSPE-mPEG as described in claim 1 are added. 2k Dissolve in chloroform to obtain a mixed solution; (2) Under ultrasonic conditions, the mixed solution was slowly added dropwise to ultrapure water within 5 min. After the addition was completed, a micro-tip ultrasonicator was used to sonicate for another 5 min at an output power of 12 W. (3) The organic solvent was removed by ultrafiltration using a 30 kDa MW cutoff centrifugal filter unit, and the CuD@PEG nanoparticles were obtained after drying.

6. Use of the nanoparticle CuD@PEG according to claim 4 in preparing a fluorescent imaging probe or in preparing an anti-oral cancer drug.

7. A biomimetic nanoparticle containing the photosensitizer copper complex according to claim 1, characterized in that: The active ingredients of the bionic nanoparticles are copper ion carrier prodrugs that can respond to active oxygen and the photosensitizer copper complex of claim 1. The bionic nanoparticles are DSPE-mPEG 2k As a scaffold, DSPE-mPEG 2k The two active ingredients are assembled together to form nanoparticles CuD@PEG, which are then coated in a hybrid cell membrane of platelet membrane and tumor stem cell membrane to obtain biomimetic nanoparticles CuD@PM. The copper ion carrier prodrug capable of responding to active oxygen is DTC-BA, and its structural formula is as follows: 。 8. The method for preparing biomimetic nanoparticles according to claim 7, characterized in that: The following steps are involved: (1) The photosensitizer copper complex, copper ion carrier prodrug DTC-BA and DSPE-mPEG as described in claim 1 are added. 2k Dissolve in chloroform to obtain a mixed solution; (2) Under ultrasonic conditions, the mixed solution was slowly added dropwise to ultrapure water within 5 min. After the addition was completed, a micro-tip ultrasonicator was used to sonicate for another 5 min at an output power of 12 W. (3) The organic solvent was removed by ultrafiltration using a 30 kDa MW cutoff centrifugal filter unit to obtain nanoparticles CuD@PEG; (4) Mixing the tumor stem cell membrane fragments and the platelet membrane fragments, and repeatedly co-extruding them through a 200 nm polycarbonate porous membrane on a membrane extruder to prepare a hybrid cell membrane; (5) The hybrid cell membrane prepared in step (4) is mixed with the CuD@PEG nanoparticles prepared in step (3), and the mixture is repeatedly co-extruded through a 100 nm polycarbonate porous membrane on an extruder to prepare biomimetic nanoparticles CuD@PM.

9. Use of the bionic nanoparticles according to claim 7 in preparing fluorescent imaging probes or in preparing anti-oral cancer drugs.